In this episode Sacha and Matthew talk about the fascinating psychedelic brews from ancient history. They question if our account of Christian history is correct, and even suggest that psychedelics are in part responsible for the very concept of communing with God. Did Moses really see a burning bush or was he just tripping? Tune in and find out!
Defiance has launched the world’s second psychedelics-focused ETF as investing in psychedelic therapy and treatment accelerates.
A new psychedelic hotline, the Fireside Project, aims to provide peer support for people under the influence of psychedelic substances.
In this episode, we’re covering what is microdosing and its purported benefits. You will learn how to microdose magic mushrooms. How to microdose psychedelics.
Microdosing is the practice of taking a small dose of a drug, in our case psilocybin, the main active ingredient in magic mushrooms. The dose is small enough that it won’t cause any perceptual changes, meaning you won’t have any hallucinations or even feel high.
This will allow you to continue to go to school, work, or get more comfortable in social settings.
According to thousands upon thousands of anecdotal stories over decades, microdosing psilocybin is purported to:
– Improve your creativity;
– Help you enter states of flow, also known as “being in the zone” or entering a mental state of total energized concentration;
– Help alleviate feelings of stress and anxiety;
– Improve focus and concentration;
– Improves relational awareness and;
– Speeds your reflexes.
We have to rely on anecdotal evidence unfortunately, because until recently, very little scientific study has been done on the subject of microdosing, though that is starting to change with many clinical studies underway.
Despite a lack of hard scientific data, the practice is sworn upon by many in high pace environments, such as Silicon Valley. A couple famous examples of microdosers include: Joe Rogan and Steve Jobs, though for the later it was more LSD microdosing.
Let me know in the comments if you want to see a video on LSD microdosing in the future.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MicrodosingMushrooms #Microdosing #MagicMushrooms
In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin.
Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled “MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience”. MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer.
Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project
And that project will be researching the effects of Psilocybin
So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS).
So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up.
MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel
and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine..
So does this mean that MindMed’s hiring decision is related to the company’s plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed’s potential product pipeline as well as the MindMed stock.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
![MindMed Nasdaq Uplisting STOCK PREDICTIONS // How Far will MindMed Go? [MMED/ MMEDF]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-77-600x338.jpeg)
Here are my MindMed NASDAQ uplisting STOCK PREDICTIONS! MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
On the day the news was announced, MMED and MMEDF gained 65.26% , rising from $2.13 to a day high of to $3.57 Though in the last few days the price had fallen, it was still up by 30.86% over the past 2 weeks. MindMed volume increased on the last day, in total, 14 million more shares were traded that the day before. This giant bump brought a lot of MindMed stock speculation which is why we’re making this episode.
Where does MindMed go from here on? MMED / MNMD is still just at the beginning of their long-term growth trajectory so we could only do our due diligence while speculating.
Some speculate that some investors might feel inclined to take profits, which is absolutely understandable. But will they take profits right away or wait for the MNMD price to go ballistic or take profits right away? What will happen to the MindMed stock when/if the do?
Others speculate that the uplisting event might create a FOMO movement which could more than 3X the stock’s price which could create a larger FOMO wave and bring MindMed’s stock price to a similar level to Compass Pathways who’s market cap is very close to MindMed’s.
On this channel, we have been repeatedly saying that investing in the psychedelic industry and specifically in Mindmed should be a long-term play and that the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval. So….
In this segment, we’ll discuss FOUR possible cases:
Timestamps:
0:00 – Intro
4:17 – Worst Case
7:48 – Probable Case
9:57 – #WINNING CASE
11:58 – APES TOGETHER STRONG CASE
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock
My psychedelic MDMA experience put me into a hole of paranoia and dysregulation. Here’s what it took for me to climb out of it
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
